Immunoglobulin (Ig) A nephropathy is considered an important cause of end-stage renal failure. Therefore, from today’s perspective, IgA nephropathy should not be classified as a benign disease. Fortunately, the treatment spectrum has expanded in recent years. In addition to oral TRF-budesonide and the DEARA drug sparsentan, which have now been approved in many countries, numerous pathogenesis-based therapies are currently in development. However, classic nephroprotective therapy options – RAAS-i, SGLT-2-i, MRA and GLP-1-RA – also continue to play an important role .
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Acute leukemia: Disease management
Priorities from the perspective of patients and family caregivers
- Bronchodilators for asthma
The early bird … gasps for air
- Chronic kidney disease (CKD)
Triage of high-risk patients – Update 2025
- AAD Annual Meeting: Review
HS and acne – what’s new?
- New perspectives for the optimization of cancer immunotherapy
Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9
- Past, present and future
Biomarkers in schizophrenia
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications